{
    "clinical_study": {
        "@rank": "146465", 
        "arm_group": [
            {
                "arm_group_label": "FF/VI 100/25 mcg + UMEC (62.5mcg)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks."
            }, 
            {
                "arm_group_label": "FF/VI 100/25 mcg + UMEC (125mcg)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks."
            }, 
            {
                "arm_group_label": "FF/VI 100/25 mcg + Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "After screening, subjects will enter a 4 week open-label run-in period with fluticasone\n      furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler\n      (DPI). Subjects will then be randomized to receive any one of the 3 treatments (umeclidinium\n      bromide [UMEC] [62.5 mcg] administered once daily via a DPI; OR UMEC [125 mcg] administered\n      once daily via a DPI; OR matching placebo administered once daily via a DPI), while\n      continuing treatment with open label FF/VI 100/25 mcg during a 12-week treatment period.\n      There will be a total of eight scheduled clinic visits at Pre-Screening (Visit0), Screening\n      (Visit 1), blinded treatment Day 1(Visit2), 2(Visit3), 28 (Visit4), 56 (Visit5), 84 (Visit6)\n      and 85 (Visit7). A follow-up phone contact will be conducted approximately 7 days after the\n      last clinic visit. The total duration of subject participation in the study from Screening\n      to Follow-up will be approximately 17 weeks."
        }, 
        "brief_title": "Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type of subject: Outpatient.\n\n          -  Informed Consent: A signed and dated written informed consent prior to study\n             participation.\n\n          -  Age:  Subjects 40 years of age or older at Visit 1.\n\n          -  Gender:  Male or female subjects.\n\n          -  A female is eligible to enter and participate in the study if she is of:\n\n          -  Non-child bearing potential (i.e., physiologically incapable of becoming pregnant,\n             including any female who is post-menopausal or surgically sterile). Surgically\n             sterile females are defined as those with a documented hysterectomy and/or bilateral\n             oophorectomy or tubal ligation. Post-menopausal females are defined as being\n             amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age\n             appropriate, >45 years, in the absence of hormone replacement therapy.\n\n        OR\n\n          -  Child bearing potential, has a negative pregnancy test at screening, and agrees to\n             one of the following acceptable contraceptive methods used consistently and correctly\n             (i.e., in accordance with the approved product label and the instructions of the\n             physician for the duration of the study - screening to follow-up contact):\n\n          -  Abstinence\n\n          -  Oral Contraceptive, either combined or progestogen alone\n\n          -  Injectable progestogen\n\n          -  Implants of levonorgestrel\n\n          -  Estrogenic vaginal ring\n\n          -  Percutaneous contraceptive patches\n\n          -  Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP\n             effectiveness criteria as stated in the product label\n\n          -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to the\n             female subject's entry into the study, and this male is the sole partner for that\n             subject.  For this definition, \"documented\" refers to the outcome of the\n             investigator's/designee's medical examination of the subject or review of the\n             subject's medical history for study eligibility, as obtained via a verbal interview\n             with the subject or from the subject's medical records.\n\n          -  Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps)\n             with a vaginal spermicidal agent (foam/gel/film/cream/suppository)\n\n          -  Diagnosis:  An established clinical history of COPD in accordance with the definition\n             by the American Thoracic Society/European Respiratory Society.\n\n          -  Smoking History:  Current or former cigarette smokers with a history of cigarette\n             smoking of >=10 pack-years [number of pack years = (number of cigarettes per day /\n             20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10\n             cigarettes per day for 20 years)].  Former smokers are defined as those who have\n             stopped smoking for at least 6 months prior to Visit 1.  Pipe and/or cigar use cannot\n             be used to calculate pack year history.\n\n          -  Severity of Disease:  A pre and post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and\n             a pre and post-albuterol/salbutamol FEV1 of <=70% of predicted normal values at Visit\n             1 (Screening) calculated using Nutrition Health and Examination Survey (NHANES) III\n             reference equations.\n\n          -  Dyspnea:  A score of >=2 on the mMRC Dyspnea Scale at Visit 1.\n\n          -  QTc Criteria:\n\n          -  QTc(F) <450 milliseconds (msec) or\n\n          -  QTc(F) <480msec for patients with QRS duration >=120msec\n\n          -  The QTc is the QT interval corrected for heart rate according to either Bazett's\n             formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual\n             overread.\n\n          -  For subject eligibility and withdrawal, QTcF will be used.\n\n          -  For purposes of data analysis, QTcF will be used as primary.\n\n          -  The QTc should be based on single or averaged QTc values of triplicate\n             electrocardiograms (ECGs) obtained over a brief recording period.\n\n        Exclusion Criteria:\n\n          -  Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant\n             during the study.\n\n          -  Asthma:  A current diagnosis of asthma.\n\n          -  Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung\n             infections (such as tuberculosis), and lung cancer are absolute exclusionary\n             conditions. A subject who, in the opinion of the investigator, has any other\n             significant respiratory conditions in addition to COPD should be excluded. Examples\n             may include clinically significant bronchiectasis, pulmonary hypertension,\n             sarcoidosis, or interstitial lung disease.\n\n          -  Other Diseases/Abnormalities:  Subjects with historical or current evidence of\n             clinically significant cardiovascular, neurological, psychiatric, renal, hepatic,\n             immunological, endocrine (including uncontrolled diabetes or thyroid disease) or\n             hematological abnormalities that are uncontrolled and/or a previous history of cancer\n             in remission for <5 years prior to Visit 1 (localized carcinoma of the skin that has\n             been resected for cure is not exclusionary).  Significant is defined as any disease\n             that, in the opinion of the investigator, would put the safety of the subject at risk\n             through participation, or which would affect the efficacy or safety analysis if the\n             disease/condition exacerbated during the study.\n\n          -  Contraindications: Any history of allergy or hypersensitivity to any\n             anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic,\n             corticosteroid (intranasal, inhaled or systemic) lactose/milk protein or magnesium\n             stearate, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy\n             or bladder neck obstruction, that, in the opinion of the study physician\n             contraindicates study participation or use of an inhaled Long acting muscarinic\n             antagonist (LAMA), Long acting beta agonist (LABA) or Inhaled corticosteroids (ICS).\n\n          -  Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit\n             1.\n\n          -  Lower respiratory tract infection: Subjects with lower respiratory tract infection\n             that required the use of antibiotics within 6 weeks prior to Visit 1.\n\n          -  Lung Resection:  Subjects with lung volume reduction surgery within the 12 months\n             prior to Visit 1.\n\n          -  12-Lead ECG:  An abnormal and clinical significant ECG finding from the 12-lead ECG\n             conducted at Visit 1.  Investigators will be provided with ECG reviews conducted by a\n             centralized independent cardiologist to assist in evaluation of subject eligibility.\n             The study investigator will determine the medical significance of any ECG\n             abnormalities.\n\n          -  Clinically significant and abnormal laboratory finding at Screening (Visit1). After\n             discussion with the Medical Monitor, the investigator may have the option to verify\n             the abnormal lab result prior to Visit2\n\n          -  Medication Prior to Spirometry:  Unable to withhold albuterol/salbutamol for the 4\n             hour period required prior to spirometry testing at each study visit.\n\n          -  Excluded Medications:  Use of the following medications are not permitted within the\n             defined time intervals prior to Visit 1and throughout the study:\n\n          -  No use within 12 weeks prior to Screening Visit 1 or thereafter at any time during\n             the study: Depot corticosteroids.\n\n          -  No use within 6 weeks prior to Screening Visit 1 or thereafter at any time during the\n             study: Systemic, oral or parenteral corticosteroids (Intra-articular corticosteroid\n             injections are permitted.), Antibiotics (for lower respiratory tract infection),\n             Cytochrome P450 3A4 strong inhibitors.\n\n          -  No use within 14 days prior to Screening Visit 1 or thereafter at any time during the\n             study: Phosphodiesterase 4 inhibitors (roflumilast).\n\n          -  No use within 10 days prior to Screening Visit 1 or thereafter at any time during the\n             study: Olodaterol and Indacaterol.\n\n          -  No use within 7 days prior to Screening Visit 1 or thereafter at any time during the\n             study: Long acting muscarinici antagonists (tiotropium, aclidinium, glycopyrronium).\n\n          -  No use within 48 hrs prior to Screening Visit 1 or thereafter at any time during the\n             study: Theophyllines, Oral leukotriene inhibitors (zafirlukast, montelukast,\n             zileuton), Salmeterol and formoterol, ICS/LABA combinations (e.g., fluticasone\n             propionate/salmeterol, mometasone furoate/formoterol fumarate, budesonide/formoterol\n             fumarate), Oral beta2-agonists Long-acting.\n\n          -  No use within 24 hrs prior to Screening Visit 1 or thereafter at any time during the\n             study: Inhaled sodium cromoglycate or nedocromil sodium.\n\n          -  No use within 12 hrs prior to Screening Visit 1 or thereafter at any time during the\n             study: Oral beta2-agonists Short-acting.\n\n          -  No use within 4 hrs prior to Screening Visit 1 or thereafter at any time during the\n             study: Inhaled short acting beta2-agonists (use of study provided prn\n             albuterol/salbutamol is permitted during the study, except in the 4-hour period prior\n             to spirometry testing.), Inhaled short-acting anticholinergics, Inhaled short-acting\n             anticholinergic/short-acting beta2-agonist combination products.\n\n          -  No use within 30 days or 5 half lives whichever is longer prior to Screening Visit 1\n             or thereafter at any time during the study: Any other investigational drug.\n\n          -  Prior enrolment in one of the replicate studies: subjects who have previously been\n             assigned a subject number (enrolled) in study 200110 that is a replicate study of\n             200109.\n\n          -  Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed\n             for greater than 12 hours a day. As-needed oxygen use (i.e., <=12 hours per day) is\n             not exclusionary.\n\n          -  Nebulized Therapy:  Regular use (prescribed for use every day, not for as-needed use)\n             of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy.\n\n          -  Pulmonary Rehabilitation Program:  Participation in the acute phase of a pulmonary\n             rehabilitation program within 4 weeks prior to Visit 1, or who will enter the acute\n             phase of a pulmonary rehabilitation program during the study.  Subjects who are in\n             the maintenance phase of a pulmonary rehabilitation program are not excluded.\n\n          -  Drug or Alcohol Abuse:  A known or suspected history of alcohol or drug abuse within\n             2 years prior to Visit 1.\n\n          -  Affiliation with Investigator Site:  A subject will not be eligible for this study if\n             he/she is an immediate family member of the participating investigator,\n             sub-investigator, study coordinator, or employee of the participating investigator.\n\n          -  Inability to read:  In the opinion of the investigator, any subject who is unable to\n             read and/or would not be able to complete a questionnaire."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "620", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119286", 
            "org_study_id": "200110"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FF/VI 100/25 mcg + Placebo", 
                    "FF/VI 100/25 mcg + UMEC (125mcg)", 
                    "FF/VI 100/25 mcg + UMEC (62.5mcg)"
                ], 
                "description": "Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.", 
                "intervention_name": "FF", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FF/VI 100/25 mcg + Placebo", 
                    "FF/VI 100/25 mcg + UMEC (125mcg)", 
                    "FF/VI 100/25 mcg + UMEC (62.5mcg)"
                ], 
                "description": "Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.", 
                "intervention_name": "VI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FF/VI 100/25 mcg + UMEC (125mcg)", 
                    "FF/VI 100/25 mcg + UMEC (62.5mcg)"
                ], 
                "description": "Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.", 
                "intervention_name": "UMEC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FF/VI 100/25 mcg + Placebo", 
                "description": "The matching placebo DPI identical in appearance to the inhaler containing active study medication.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bromides", 
                "Fluticasone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "long acting beta2- receptor agonist", 
            "long acting muscarininc receptor antagonist", 
            "dry powder inhaler", 
            "safety", 
            "COPD", 
            "inhaled corticosteroid", 
            "efficacy", 
            "fluticasone furoate/vilanterol", 
            "umeclidinium bromide"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36608"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85006"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huntington Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92647"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DeLand", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32825"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coeur D'Alene", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83814"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunset", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70584"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Charles", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63301"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28207"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gaffney", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29340"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rock Hill", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29732"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newport News", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23606"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kralupy nad Vltavou", 
                        "country": "Czech Republic", 
                        "zip": "278 01"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic", 
                        "zip": "772 00"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava - Poruba", 
                        "country": "Czech Republic", 
                        "zip": "70868"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4", 
                        "country": "Czech Republic", 
                        "zip": "140 46"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tabor", 
                        "country": "Czech Republic", 
                        "zip": "390 19"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Teplice", 
                        "country": "Czech Republic", 
                        "zip": "415 10"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "70378"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dillingen", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "89407"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "80339"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "60596"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kassel", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "34121"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neu-Isenburg", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "63263"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schwerin", 
                        "country": "Germany", 
                        "state": "Mecklenburg-Vorpommern", 
                        "zip": "19055"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "state": "Niedersachsen", 
                        "zip": "30159"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "state": "Niedersachsen", 
                        "zip": "30173"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osnabrueck", 
                        "country": "Germany", 
                        "state": "Niedersachsen", 
                        "zip": "49074"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dueren", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "52349"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "45359"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "45355"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koeln", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "51069"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Witten", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "58452"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koblenz", 
                        "country": "Germany", 
                        "state": "Rheinland-Pfalz", 
                        "zip": "56068"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "state": "Sachsen-Anhalt", 
                        "zip": "39112"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01069"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzg", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04109"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04207"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04357"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04103"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reinfeld", 
                        "country": "Germany", 
                        "state": "Schleswig-Holstein", 
                        "zip": "23858"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany", 
                        "state": "Thueringen", 
                        "zip": "07548"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schmoelln", 
                        "country": "Germany", 
                        "state": "Thueringen", 
                        "zip": "04626"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14059"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13156"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10119"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20253"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22299"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "705-717"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kangwon-do", 
                        "country": "Korea, Republic of", 
                        "zip": "220-701"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "134-701"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "130-702"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "152-703"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "156-707"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Czech Republic", 
                "Germany", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Trough FEV1 on Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes pre-dose on Treatment Day 1.", 
            "measure": "Trough FEV1 on Day 85", 
            "safety_issue": "No", 
            "time_frame": "Day 85"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119286"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 15 minutes, 30 minutes, 1 hour, 3 hours and 6 hours.", 
                "measure": "Weighted mean (WM) 0-6 hour FEV1 obtained post-dose on Day 84", 
                "safety_issue": "No", 
                "time_frame": "Day 84"
            }, 
            {
                "description": "Safety measurements Incidence of adverse events (AE) Vital signs (pulse rate, systolic and diastolic blood pressure) Incidence of COPD exacerbation will assessed", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "Day -28 (Screening) up to Follow up."
            }, 
            {
                "description": "Quality of life was assessed by St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) and COPD Assessment Test (CAT).", 
                "measure": "Health outcomes and Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Pre screening up to Follow up."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}